Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy - PubMed (original) (raw)

. 2009 Sep;135(9):1239-44.

doi: 10.1007/s00432-009-0565-9. Epub 2009 Mar 10.

Affiliations

• PMID: 19277712
• DOI: 10.1007/s00432-009-0565-9

Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy

Jochen Tuettenberg et al. J Cancer Res Clin Oncol. 2009 Sep.

Abstract

Purpose: Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy.

Patients and methods: A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy.

Results: While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (+/-0.9) months and a mean overall survival of 17.8 (+/-1.5) months, an unusually high rate of distant recurrences was observed (62.5%).

Conclusion: Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.

PubMed Disclaimer

Similar articles

• Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
  Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Tuettenberg J, et al. J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40. doi: 10.1007/s00432-004-0620-5. Epub 2004 Sep 28. J Cancer Res Clin Oncol. 2005. PMID: 15565458
• [Treatment of recurrent glioblastoma with single-agent bevacizumab].
  Sinkó D, Nemeskéri C. Sinkó D, et al. Orv Hetil. 2016 Mar 27;157(13):500-3. doi: 10.1556/650.2015.30395. Orv Hetil. 2016. PMID: 26996897 Hungarian.
• UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.
  Herrlinger U, Rieger J, Steinbach JP, Nägele T, Dichgans J, Weller M. Herrlinger U, et al. J Neurooncol. 2005 Feb;71(3):295-9. doi: 10.1007/s11060-004-1726-y. J Neurooncol. 2005. PMID: 15735920 Clinical Trial.
• Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.
  Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. Verhoeff JJ, et al. BMC Cancer. 2009 Dec 16;9:444. doi: 10.1186/1471-2407-9-444. BMC Cancer. 2009. PMID: 20015387 Free PMC article. Review.
• Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
  Miletic H, Niclou SP, Johansson M, Bjerkvig R. Miletic H, et al. Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444. Expert Opin Ther Targets. 2009. PMID: 19335067 Review.

Cited by

• Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.
  Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Wagle N, et al. Pharmgenomics Pers Med. 2010;3:79-85. doi: 10.2147/pgpm.s7940. Epub 2010 Jun 9. Pharmgenomics Pers Med. 2010. PMID: 23226044 Free PMC article.
• Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
  Seiz M, Nölte I, Pechlivanis I, Freyschlag CF, Schmieder K, Vajkoczy P, Tuettenberg J. Seiz M, et al. Neurosurg Rev. 2010 Jul;33(3):375-81; discussion 381. doi: 10.1007/s10143-010-0253-x. Epub 2010 Mar 20. Neurosurg Rev. 2010. PMID: 20306105
• Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia.
  Jacobs VL, Landry RP, Liu Y, Romero-Sandoval EA, De Leo JA. Jacobs VL, et al. Neuro Oncol. 2012 Feb;14(2):119-31. doi: 10.1093/neuonc/nor194. Epub 2011 Nov 15. Neuro Oncol. 2012. PMID: 22086978 Free PMC article.
• Neuroimaging classification of progression patterns in glioblastoma: a systematic review.
  Piper RJ, Senthil KK, Yan JL, Price SJ. Piper RJ, et al. J Neurooncol. 2018 Aug;139(1):77-88. doi: 10.1007/s11060-018-2843-3. Epub 2018 Mar 30. J Neurooncol. 2018. PMID: 29603080
• Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
  Cho SJ, Kim HS, Suh CH, Park JE. Cho SJ, et al. Korean J Radiol. 2020 Jul;21(7):908-918. doi: 10.3348/kjr.2019.0898. Korean J Radiol. 2020. PMID: 32524791 Free PMC article.

References

1. 1. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 - PubMed
2. 1. Clin Cancer Res. 2002 Jan;8(1):221-32 - PubMed
3. 1. Neuro Oncol. 2007 Jul;9(3):335-42 - PubMed
4. 1. Curr Pharm Des. 2006;12(3):341-9 - PubMed
5. 1. J Neurosurg. 1987 Jun;66(6):865-74 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information